Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

10603	Companies
225009	Keywords
153732	Articles
119071	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 07/01/2025 at 13:20, 11 months 19 days ago

Bio Usawa to Commercialize FYB201 in Sub-Saharan Africa

Formycon AG FYB201 Sub-Saharan Africa Bio Usawa Diabetic Macular Edema
PRESS RELEASE

published on 07/01/2025 at 13:15, 11 months 19 days ago

Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Bio Usawa partners with Formycon AG for the commercialization of FYB201/BioUcenta™ (ranibizumab) in Sub-Saharan Africa, expanding access to ophthalmic treatment for diabetic complications

Formycon AG Commercialization FYB201 Bio Usawa BioUcenta
BRIEF

published on 06/27/2025 at 15:56, 11 months 23 days ago

Formycon Successfully Places EUR 70 Million Bond Amid High Demand

Biosimilars Investor Interest Capital Market EUR 70 Million Formycon Bond
PRESS RELEASE

published on 06/27/2025 at 15:51, 11 months 23 days ago

Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Formycon AG successfully and entirely places EUR 70 million bond 2025/2029 following oversubscription, interest rate fixed at 7.00% p.a

Formycon AG Interest Rate Oversubscription EUR 70 Million Bond 2025/2029
BRIEF

published on 06/27/2025 at 15:50, 11 months 23 days ago

Formycon Secures EUR 70 Million Floating Rate Bond

Formycon AG Financial Issuance Biosimilar Development EUR 70 Million Bond Floating Rate Bond
PRESS RELEASE

published on 06/27/2025 at 15:45, 11 months 23 days ago

EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
Formycon AG successfully places EUR 70 million senior unsecured floating rate bond, issued with a maturity of 4 years, financed for biosimilar product portfolio development

Formycon AG Financial Market Senior Unsecured Bond Biosimilar Products EUR 70 Million
BRIEF

published on 06/26/2025 at 06:35, 11 months 24 days ago

Teva to Commercialize Formycon’s Biosimilar Fymskina® in Germany

Germany Biosimilar Formycon Teva Fymskina®
PRESS RELEASE

published on 06/26/2025 at 06:30, 11 months 24 days ago

Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Teva partners with Formycon for commercialization of Stelara biosimilar FYB202 (ustekinumab) as Fymskina in Germany. Market launch planned in Q3 2025

Biosimilar Formycon Teva Stelara Fymskina
BRIEF

published on 06/25/2025 at 06:35, 11 months 25 days ago

Valorum Biologics Partners with Formycon for FYB203 in North America

Partnership Biosimilars Commercialization Ophthalmology North America Market
PRESS RELEASE

published on 06/25/2025 at 06:30, 11 months 25 days ago

U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Valorum Biologics LLC partners with Formycon AG for commercialization of Eylea biosimilar FYB203/AHZANTIVE in the United States and Canada. Major shareholder ATHOS KG supports financing

Formycon AG Eylea Biosimilar Valorum Biologics Commercialization Partner ATHOS KG

Accesswire

Published on 06/20/2026 at 01:00, 16 hours 48 minutes ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 17 hours 48 minutes ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 13 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 16 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 16 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 06:00, 11 hours 48 minutes ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 21 hours 30 minutes ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 22 hours 47 minutes ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:29, 23 hours 19 minutes ago

Designated Person Notification
Published on 06/19/2026 at 18:00, 23 hours 48 minutes ago

Successful issue of a CHF 100 million green bond

Les Echos

Published on 06/19/2026 at 19:33, 22 hours 15 minutes ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 22 hours 24 minutes ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 1 day 23 hours ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 2 days ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 2 days ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026

View all LES ECHOS COMFI WIRE